TuHURA Biosciences Achieves Compliance with Nasdaq Listing Standards Following Remarkable Stock Recovery

TuHURA Biosciences Regains Nasdaq Compliance

TuHURA Biosciences, Inc. (NASDAQ:HURA), a pivotal player in the Phase 3 immuno-oncology sector, has recently announced a significant milestone. As of February 26, 2026, the company received official communication from the Nasdaq Stock Market, confirming its compliance with the minimum bid price requirement of $1.00 per share, in accordance with Nasdaq Listing Rule 5550(a)(2).

Over a consecutive span of eleven business days, from February 10 to February 25, TuHURA's common stock closed at, or exceeded, the benchmark $1.00, thereby resolving the previous compliance issue. Dr. James Bianco, President and CEO of TuHURA Biosciences, expressed satisfaction with the company’s regained compliance, emphasizing the focus on advancing their therapeutic pipeline.

Strategic Focus on Development and Trials

TuHURA is currently accelerating its Phase 3 trial for its leading drug candidate, IFX-2.0, aimed at treating Merkel Cell Carcinoma. This immuno-oncological treatment is designed to augment the efficacy of existing therapies by overcoming resistance commonly observed in cancer treatment protocols.

In addition to enhancing the current trial, the company is poised to initiate a Phase 2 study for TBS 2025, a promising VISTA inhibiting antibody therapy designed for treating relapsed and refractory NPM1 mutated Acute Myeloid Leukemia (AML). This strategic direction positions TuHURA as a significant contributor to innovative treatment methodologies in oncology.

Moreover, the company is channeling efforts into developing first-in-class immune modulating antibody drug conjugates. These conjugates aim to utilize Delta Opioid Receptor technology to tackle myeloid-derived suppressor cells that, if left unchecked, can inhibit T cell activity and lead to therapy resistance. Such innovative approaches highlight TuHURA's commitment to pioneering solutions against challenges that currently hinder the effectiveness of cancer therapies.

Commitment to Innovation

Through its dedicated research and development, TuHURA is aligned with its vision of tackling primary and acquired resistance to therapies that significantly diminish treatment outcomes for the majority of cancer patients. The advancements in its pipeline signify a strong commitment to fighting cancer and improving patients' lives.

According to industry insights, the role of immunotherapy continues to pivot toward personalized and adaptive approaches, where companies like TuHURA can play an essential part in achieving breakthrough treatments. Hence, the significance of adhering to listing standards on Nasdaq cannot be overstated, as it ensures investor confidence and funding opportunities, many of which are vital for ongoing research.

As TuHURA Biosciences moves forward, stakeholders are advised to stay informed about the company's progress through its official channels, including www.tuhurabio.com, and its social media platforms including Facebook, X, and LinkedIn.

Conclusion

The journey ahead for TuHURA Biosciences promises to be rife with potential not only for the company but for the many patients awaiting innovative therapies to combat cancer. By regaining compliance with Nasdaq, TuHURA has demonstrated resilience and dedication to advancing viable solutions in the field of immuno-oncology. Investors and medical communities alike look forward to witnessing the positive impact of TuHURA's recent developments in the healthcare landscape.